Dr. Nathalie H. Urrunaga, MD

Dr. Urrunaga practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Urrunaga's NPI, 1790945889, was assigned on June 11, 2008. Dr. Urrunaga graduated from Cayetano Heredia University in 2006. Dr. Urrunaga's Maryland license number on file is D73538.

Dr. Urrunaga's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Urrunaga's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Urrunaga is also affiliated with University of Maryland Medical Center Midtown Campus. The medical group on file is University of Maryland Medical Center Gastroenterology and Hepatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Urrunaga practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Urrunaga's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Urrunaga is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Urrunaga has a license on file in Maryland.

Dmand AI lists acid reflux, cirrhosis of the liver, colonoscopy, fatty liver, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Urrunaga treats.

CMS data shows 383 Medicare services from Dr. Urrunaga across 8 procedure codes in 2024, for 220 Medicare patients. Medicare paid $39,703 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 220 Medicare patients who saw Dr. Urrunaga in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Urrunaga's median patient age at 63, with 38% women.

In 2024, Dr. Urrunaga wrote 250 Medicare Part D claims for 40 patients. 90% of them were for generic drugs. CMS names the drug for 164 of them, across 8 drugs with 11 or more claims each, at $22,197 in total drug cost. In 2023, CMS named 216 claims across 9 drugs.

Dr. Urrunaga accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Urrunaga as offering telehealth. CMS counts 40 procedures of colonoscopy by Dr. Urrunaga, more than 59% of the clinicians it reports for that procedure.

Dmand AI links 32 papers to Dr. Urrunaga, published from 2012 to 2024. 2022 was the busiest year, with 7. The most frequent topics are Liver Transplantation, Graft Survival and Hepatitis C. Dr. Urrunaga has published most often in Clin Res Hepatol Gastroenterol. Dr. Urrunaga's most frequent co-authors are Don C. Rockey, MD, Ayse Leyla Mindikoglu, MD, MPH and Jean-Pierre Raufman, MD.

CMS Open Payments shows 51 general payments to Dr. Urrunaga from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Gilead Sciences, Inc. paid the most, $3,755.

Dr. Urrunaga graduated from Cayetano Heredia University in 2006.

Dr. Urrunaga is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 13. Check the plan with the practice before a visit.